Sealed Radioactive Sources in Brachytherapy
Sealed radioactive sources in brachytherapy provide localised cancer treatment with minimal radiation exposure to surrounding tissues. Image for illustration only. People depicted are models.
Sealed radioactive sources in brachytherapy provide localised cancer treatment with minimal radiation exposure to surrounding tissues. Image for illustration only. People depicted are models.
Auger electron-emitting radionuclides offer innovative therapeutic potential through highly localised DNA damage with minimal collateral effects.
Yttrium-90 microspheres therapy utilises brachytherapy to treat liver cancer, offering precise tumour targeting and extended survival.
Tin-117m HTC is a novel therapeutic radiopharmaceutical designed for targeted arthritis treatment using conversion electron brachytherapy technology.
Rhenium-188 SSS/Lipiodol combines targeted delivery with beta radiation, offering hope for advanced hepatocellular carcinoma patients.
Rhenium-186 Nano Liposomes deliver targeted beta radiation directly to tumours, minimising surrounding tissue damage.
Ankylosing Spondylitis is a progressive inflammatory condition targeting the spine, leading to chronic pain and joint fusion.
Pancreatic cancer treatment has advanced significantly with the introduction of OncoSil brachytherapy for pancreatic cancer therapy.
Holmium-166 Phytate, initially developed for chronic synovitis, has shown significant promise in phase I/II clinical trials.
Holmium-166 Chitosan, a groundbreaking radiopharmaceutical, offers new hope in treating hepatocellular carcinoma with targeted therapy.
Holmium-166 microspheres, by delivering localized radiation, significantly enhance the therapeutic approach to inoperable liver cancer treatment.
Radiotherapy machines are advanced tools that deliver high-energy radiation to treat cancer. From linear accelerators to cyberKnife and tomotherapy.
Brachytherapy techniques have been a powerhouse in the treatment of cancer since the beginning of the twentieth century.
Yttrium-90 radioembolization is a well-established therapy for the treatment of hepatocellular carcinoma.